While the approval of targeted agents such as FLT3 and IDH inhibitors in R/R AML patients with these mutations has offered new therapeutic options, such druggable mutations are only present in less than half of AML patients [3–6], and even such patients typically progress within months of receiving these therapies highlighting the high unmet clinical need in R/R AML. Here, FLT3 is linked to acute myeloid leukemia.